Seer, Inc. Class A (SEER) Dividend History

Seer, Inc. Class A (SEER) is a biotechnology company focused on developing advanced proteomics technologies to enable detailed analysis of proteins in biological samples. Its platform aims to facilitate breakthroughs in drug discovery, diagnostics, and research by providing high-throughput, precise, and scalable protein measurement solutions.

3800 Bridge Parkway, Suite 102, Redwood City, CA, 94065
Phone: 650-453-0000
Website: https://www.seer.bio

Dividend History

Seer, Inc. Class A currently does not pay dividends

Company News

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

Seer, Inc. and Korea University are launching a large-scale proteomics study to identify biomarkers for early cancer detection in young adults, leveraging Seer's Proteograph platform and Thermo Scientific's Orbitrap Astral mass spectrometer.

GlobeNewswire Inc.
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

Seer, Inc. will showcase new findings at the 21st Annual US Human Proteome Organization (HUPO) Conference, including a case study on a novel co-delivery therapeutic platform for targeting cancer vulnerabilities with siRNA and mRNA therapeutics.

GlobeNewswire Inc.
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery

Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation

GlobeNewswire Inc.
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study

Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects

GlobeNewswire Inc.
Seer, Inc. (SEER) Reports Q1 Loss, Misses Revenue Estimates

Seer (SEER) delivered earnings and revenue surprises of -3.23% and 13.51%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research

Featured Companies: MRSN

Dividend data last updated 06/07/2025 06:38:15 UTC